29.45
Tg Therapeutics Inc stock is traded at $29.45, with a volume of 2.18M.
It is up +2.35% in the last 24 hours and down -21.21% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$28.77
Open:
$28.74
24h Volume:
2.18M
Relative Volume:
1.11
Market Cap:
$4.67B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-267.68
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
+4.86%
1M Performance:
-21.21%
6M Performance:
-4.65%
1Y Performance:
+20.68%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TGTX
Tg Therapeutics Inc
|
29.45 | 4.40B | 264.79M | -14.36M | -28.11M | -0.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-25 | Resumed | Goldman | Neutral |
Oct-29-24 | Initiated | TD Cowen | Buy |
Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
Jun-26-23 | Resumed | Jefferies | Buy |
May-20-22 | Initiated | BofA Securities | Underperform |
Feb-23-22 | Reiterated | B. Riley Securities | Buy |
Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
Apr-20-21 | Initiated | Goldman | Neutral |
Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
Sep-01-20 | Initiated | JP Morgan | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Jun-05-20 | Initiated | Evercore ISI | Outperform |
Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
Nov-27-19 | Resumed | B. Riley FBR | Buy |
Feb-06-19 | Resumed | Jefferies | Buy |
Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
Nov-14-17 | Resumed | H.C. Wainwright | Buy |
Apr-25-17 | Initiated | Jefferies | Buy |
Mar-06-17 | Reiterated | FBR & Co. | Outperform |
Oct-06-16 | Resumed | Brean Capital | Buy |
May-27-16 | Initiated | SunTrust | Buy |
Dec-01-15 | Initiated | FBR Capital | Outperform |
Sep-09-15 | Initiated | Raymond James | Strong Buy |
Aug-12-15 | Resumed | H.C. Wainwright | Buy |
Jun-19-15 | Reiterated | Brean Capital | Buy |
Dec-11-14 | Reiterated | ROTH Capital | Buy |
Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Will TG Therapeutics Inc. Reverse From Oversold ConditionsEarnings Growth Report & Fast Gain Stock Trading Tips - classian.co.kr
TG Therapeutics: Looking For The Stimulus For A Turnaround (NASDAQ:TGTX) - Seeking Alpha
Fibonacci Support Holding Strong in TG Therapeutics Inc.2025 Trading Recap & Advanced Swing Trade Entry Alerts - metal.it
TG Therapeutics (NASDAQ:TGTX) Advances 5.1% This Week, Taking Three-year Gains to 302% - 富途牛牛
Why TG Therapeutics Inc. stock attracts strong analyst attentionJobs Report & Capital Efficiency Focused Ideas - mustnews.co.kr
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You Think - Yahoo Finance
Is TG Therapeutics Inc. in a long term uptrendWeekly Profit Recap & Proven Capital Preservation Tips - thegnnews.com
TG Therapeutics Inc. Sees Spike in Bullish Option FlowShort Setup & Reliable Momentum Entry Alerts - beatles.ru
Intraday Charts Show Spike in TG Therapeutics Inc. ActivityWeekly Market Summary & Weekly Watchlist for Hot Stocks - thegnnews.com
How Investors Are Reacting To TG Therapeutics (TGTX) Raising 2025 Revenue Guidance After Strong Q2 Results - simplywall.st
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
TG Therapeutics Faces Regulatory and Legal Challenges Amid AI Risks - AInvest
Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail
TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest
TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest
TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest
Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest
Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest
TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest
TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey
TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛
TGTX Stock Falls 14.1% Amid Market Volatility - AInvest
TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest
TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks
TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize
Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest
TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com
New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN
TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Rob - GuruFocus
TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post
TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks
TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest
Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛
Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - Investor's Business Daily
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):